Analyst Science Day


  • Client was a small biopharmaceutical start-up that had recently IPO’ed with one product in their pipeline
  • Client had recently completed two phase 3 studies, with both studies demonstrating efficacy and safety of new drug
  • An analyst science day was organized to communicate efficacy and safety to the investor community


  • Data to communicate was in raw, non-digital form, with no slides made for presentation
  • Key opinion leaders to be identified as presenters to investors because of existing reputation and influence in medical field
  • Client had minimal experience in communicating new clinical data to a large investor audience


  • For a publicly traded company, Xelay Acumen developed and organized content and presentations for Science Day with financial analyst community, including coordination with with external speakers, 2 days after primary data presented as a late-breaking oral presentation for the first time